mRNA Therapeutics in Erprobung gibt es schon länger.

Hier ein aktueller Review-Artikel von Ugur Sahin:

https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01348-0

mRNA therapeutics in cancer immunotherapy

Molecular Cancer 20, 69 (2021)

Abstract

Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment or peptide and lends itself to a broad range of pharmaceutical applications, including different modalities of cancer immunotherapy. With the ease of rapid, large scale Good Manufacturing Practice-grade mRNA production, mRNA is ideally poised not only for off-the shelf cancer vaccines but also for personalized neoantigen vaccination. The ability to stimulate pattern recognition receptors and thus an anti-viral type of innate immune response equips mRNA-based vaccines with inherent adjuvanticity. Nucleoside modification and elimination of double-stranded RNA can reduce the immunomodulatory activity of mRNA and increase and prolong protein production. In combination with nanoparticle-based formulations that increase transfection efficiency and facilitate lymphatic system targeting, nucleoside-modified mRNA enables efficient delivery of cytokines, costimulatory receptors, or therapeutic antibodies. Steady but transient production of the encoded bioactive molecule from the mRNA template can improve the pharmacokinetic, pharmacodynamic and safety properties as compared to the respective recombinant proteins. This may be harnessed for applications that benefit from a higher level of expression control, such as chimeric antigen receptor (CAR)-modified adoptive T-cell therapies. This review highlights the advancements in the field of mRNA-based cancer therapeutics, providing insights into key preclinical developments and the evolving clinical landscape.

Dazu auch passend diese US Patent Application von Ugur Sahin:

https://patents.google.com/patent/US20210290746A1/en

Individualized Vaccines for Cancer

Abstract
The present invention is in the field of tumor immunotherapy. In particular, the present invention provides individualized cancer vaccines specific for a patients tumor based on a transcriptome analysis in a tumor specimen of the patient for RNA transcripts which are excessively upregulated in one or more cancer cells of said patient. These individualized cancer vaccines when administered to the patient induce an immune response against tumor-associated antigens expressed in a tumor of the patient by the RNA transcripts which are excessively upregulated in one or more cancer cells of said patient. Due to the excessive upregulation of the RNA transcripts, the individualized cancer vaccines are effective for vaccination of a subject and for breaking the self-tolerance against tumor-associated antigens which are self-proteins in said subject.

Schönen Gruß an Paranoia, für den Google nur eine private Firma ist. Trotzdem zeigt sie die Patente an, die 18 Monate nach der Einreichung des Patents beim USPTO offen gelegt wurden, gerade so, wie google scholar auch die Papers in verschiedenen wissenschaftlichen Zeitschriften anzeigt. Es ist einfach die bequemste Suchmaschine, im Vergleich zu USPTO.gov oder depatisnet.de.